Cardiff Oncology, Inc.CRDFNASDAQ
Loading
Year-over-year revenue growth rate
3Y CAGR
+39.7%/yr
Quarterly compound
Percentile
P95
Near historical high
vs 3Y Ago
2.7x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 102.50% |
| Q3 2025 | -0.83% |
| Q2 2025 | 11.01% |
| Q1 2025 | -27.81% |
| Q4 2024 | -8.48% |
| Q3 2024 | 1.23% |
| Q2 2024 | -20.49% |
| Q1 2024 | 31.41% |
| Q4 2023 | 10.64% |
| Q3 2023 | 30.56% |
| Q2 2023 | 30.12% |
| Q1 2023 | -35.16% |
| Q4 2022 | 37.63% |
| Q3 2022 | 2.20% |
| Q2 2022 | 22.97% |
| Q1 2022 | -44.36% |
| Q4 2021 | 54.65% |
| Q3 2021 | 26.47% |
| Q2 2021 | -5.56% |
| Q1 2021 | -39.63% |
| Q4 2020 | -12.31% |
| Q3 2020 | 216.28% |
| Q2 2020 | -36.76% |
| Q1 2020 | -26.55% |
| Q4 2019 | 79.11% |
| Q3 2019 | -62.55% |
| Q2 2019 | -14.81% |
| Q1 2019 | 107.69% |
| Q4 2018 | -11.73% |
| Q3 2018 | -20.97% |
| Q2 2018 | 11.66% |
| Q1 2018 | -45.87% |
| Q4 2017 | 50.01% |
| Q3 2017 | 20.90% |
| Q2 2017 | 7.34% |
| Q1 2017 | 39.76% |
| Q4 2016 | -23.69% |
| Q3 2016 | -13.82% |
| Q2 2016 | -14.18% |
| Q1 2016 | 52.51% |